Search

Your search keyword '"Roland Lichem"' showing total 2 results
Start Over Author "Roland Lichem" Language english
2 results on '"Roland Lichem"'

1. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysisCapsule Summary

Author

Thomas Graier, MD, Wolfgang Weger, MD, Paul-Gunther Sator, MD, Wolfgang Salmhofer, MD, Barbara Gruber, MD, Constanze Jonak, MD, Claudia Kölli, MD, Martina Schütz-Bergmayr, MD, Igor Vujic, MD, Gudrun Ratzinger, MD, Nina Häring, MD, Clemens Painsi, MD, PhD, Knut Prillinger, MD, Alexander Mlynek, MD, Hans Skvara, MD, Hannes Trattner, MD, Adrian Tanew, MD, Roland Lichem, MD, Christina Ellersdorfer, MD, Franz Legat, MD, Alexandra Gruber-Wackernagel, MD, Angelika Hofer, MD, Erich Schmiedberger, MSc, Wolfram Hoetzenecker, MD, PhD, Robert Müllegger, MD, Werner Saxinger, MD, Franz Quehenberger, PhD, and Peter Wolf, MD

Subjects
apremilast, drug survival, psoriasis, Dermatology, RL1-803
Abstract

Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction. Methods: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry. Results: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively. Limitations: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment. Conclusion: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

Published
2021
Full Text
View/download PDF

2. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

Author

Roland Lichem, Alexandra Gruber-Wackernagel, Paul-Gunther Sator, Werner Saxinger, Hannes Trattner, Igor Vujic, Nina Häring, Constanze Jonak, Martina Schütz-Bergmayr, Robert R. Müllegger, Gudrun Ratzinger, Franz J. Legat, Wolfgang Weger, Clemens Painsi, Wolfram Hoetzenecker, Claudia Kölli, Alexander Mlynek, Knut Prillinger, Adrian Tanew, Angelika Hofer, Hans Skvara, Wolfgang Salmhofer, Christina Ellersdorfer, Franz Quehenberger, Barbara Gruber, Erich Schmiedberger, Thomas Graier, and Peter Wolf

Subjects
Drug, medicine.medical_specialty, PP, per protocol, media_common.quotation_subject, Arthritis, apremilast, Dermatology, Intertriginous, LOCF, last observation carried forward, Psoriasis Area and Severity Index, drug survival, Internal medicine, Psoriasis, Medicine, media_common, business.industry, Hazard ratio, psoriasis, medicine.disease, HR, hazard ratio, PASI, psoriasis area and severity index, PsoRA, Psoriasis Registry Austria, Concomitant, Original Article, Apremilast, business, SD, standard deviation, medicine.drug
Abstract

Background Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction. Methods This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry. Results Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively. Limitations Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment. Conclusion Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results